Cells (Oct 2022)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer

  • Stefano Cavalieri,
  • Mara Serena Serafini,
  • Andrea Carenzo,
  • Silvana Canevari,
  • Deborah Lenoci,
  • Federico Pistore,
  • Rosalba Miceli,
  • Stefania Vecchio,
  • Daris Ferrari,
  • Cecilia Moro,
  • Andrea Sponghini,
  • Alessia Caldara,
  • Maria Cossu Rocca,
  • Simona Secondino,
  • Gabriella Moretti,
  • Nerina Denaro,
  • Francesco Caponigro,
  • Emanuela Vaccher,
  • Gaetana Rinaldi,
  • Francesco Ferraù,
  • Paolo Bossi,
  • Lisa Licitra,
  • Loris De Cecco

DOI
https://doi.org/10.3390/cells11193176
Journal volume & issue
Vol. 11, no. 19
p. 3176

Abstract

Read online

Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammation status is related to tumor prognosis. This study aims to evaluate the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The inflammatory signature was assessed on 123 R/M HNSCC patients, enrolled in the multicenter trial B490 receiving first-line cetuximab plus platinum-based chemotherapy. The primary endpoint of the study was progression free survival (PFS), while secondary endpoints were overall survival (OS) and objective response rate (ORR). The patient population was subdivided into 3 groups according to the signature score groups. The four-genes-signature proved a significant prognostic value, resulting in a median PFS of 9.2 months in patients with high vs. 6.2 months for intermediate vs. 3.9 months for low values (p = 0.0016). The same findings were confirmed for OS, with median time of 18.4, 13.4, and 7.5 months for high, intermediate, and low values of the score, respectively (p = 0.0001). When ORR was considered, the signature was significantly higher in responders than in non-responders (p = 0.0092), reaching an area under the curve (AUC) of 0.65 (95% CI: 0.55–0.75). Our findings highlight the role of inflammation in the response to cetuximab and chemotherapy in R/M-HNSCC and may have translational implications for improving treatment selection.

Keywords